Impersonal research, traced to filings. An evidence-first read of whether Microchip Technology's move up the value chain is real, well-stewarded, and still underappreciated — the same for every reader, from SEC EDGAR 10-K + 8-K filings. This is not personalized advice or a recommendation to any specific person. As of 24 Jul 2026. Disclosures.
How it scores
Seven dimensions, 0–5 — the baseline everyone has (28%) plus the revealed-behaviour Analysis Bridge (72%). The method →
Baseline
Analysis Bridge
The evidence, dimension by dimension
Execution (do-side)
4/5Recovery plan is converting to numbers, not slideware: FY26 sales +7.1%, gross margin +160bp to 57.7%, operating margin 6.7%→10.4%, inventory cut $250M (251→185 days) and distributor DOI 33→26; Q4 FY26 revenue beat its own guidance midpoint (+35% YoY). Fab 2 closure executed on schedule. Held back from 5 only because the base is a deep-trough restart and margins remain far below the FY23 peak (36.9% OpM).
Say/do credibility
4/5Say/do reconciles well through the worst inventory downcycle in a decade: the Dec-2024 Fab 2 closure promise ($90M savings, Sep-25 shutdown) was delivered (completed May 2025, $21.8M charges taken); the March-2025 recovery plan promised cost cuts, inventory reduction and a return to growth — all three delivered in FY26 (inventory down $250M, sales up 7.1%, guidance beaten). Dividend maintained as promised. Marked down from 5 because the dividend was sustained partly by a $1.45B preferred raise and rising debt (delivered on the letter of the promise but with balance-sheet cost), and the sharpest guidance test (June-2026) is still forward.
Strategy — IP & partnerships
4/5Genuine up-chain franchise, not a merchant commodity part: proprietary MCU/analog architectures with a sticky development-tool ecosystem, ~101,000 customers, stable ASPs, SuperFlash embedded-flash IP licensed to foundries for royalties, defense-grade FPGA/security IP, and the TSS strategy that bundles hardware+software+services to raise silicon content per socket. 64-bit PIC64 RISC-V entry (July 2024) and 3nm PCIe Gen6 switch extend the mix toward AI-data-center/defense. Patent book 2026–2045. Not a 5: highly acquisitive, competes partly on being 'one of the lowest-cost producers,' and analog/MCU still ride the broad semi cycle.
Governance & stewardship
3/5Long-tenured, shareholder-returns-oriented board (dividend since 2002, ~$8.61B cumulative common dividends) and disciplined manufacturing right-sizing. But real flags: leverage runs high ($5.54B debt) and the trough dividend was defended by issuing $1.45B of 7.50% mandatory-convertible preferred (dilution/fixed-charge cost); founder Steve Sanghi returned as CEO/President amid CEO turnover (5.02 events across 2025–2026), signaling succession instability; and long-running IRS/Malaysian transfer-pricing disputes (2007–2015 IRS settled Sep-2025). Adequate, not exemplary.
Margins over the cycle
Operating margin and return on capital across the last decade of SEC filings. A structural climb up the value chain holds its gains through the down-cycle; a commodity name gives them back. Structural vs cyclical →
From SEC EDGAR XBRL.
The say/do credibility ledger
What management promised, versus what the filings show they delivered — the single largest weight in the read.
| Promise | When | Status | What the filings show |
|---|---|---|---|
| Close Fab 2 (Tempe) to resize manufacturing and generate ~$90M annual cash savings, shutting down in the Sep-2025 quarter; savings realized starting the June-2026 quarter on a FIFO basis. | 2024-12-02 (8-K Item 2.05) | Delivered | 10-K FY2026 confirms Fab 2 closure was completed in May 2025 and process technologies transferred to Fab 4/5. FY26 special charges included $21.8M related to the Tempe closure — i.e., the action executed on schedule; savings-realization window (June-2026 qtr onward) is consistent with the original FIFO timing. 8-K 2024-12-02 vs 10-K FY2026 Item 1 'Wafer Fabrication' and Item 7 'Special Charges and Other, Net' ($21.8M Tempe closure) |
| Business recovery plan (March 2025) / 'nine-point recovery plan' to cut costs, reduce inventory and return to revenue growth after a severe customer-inventory correction. | 2025-03 (10-K MD&A); reiterated Q4 FY26 8-K 2026-05-07 | Delivered | FY26 net sales rose 7.1% to $4,713.1M (all product lines/geographies up); balance-sheet inventory cut from $1.29B to $1.04B (251→185 days) and distributor days-of-inventory from 33 to 26; gross margin recovered 56.1%→57.7% and operating margin 6.7%→10.4%. Q4 FY26 (Mar-2026 qtr) revenue $1.311B beat the $1.260B guidance midpoint, +35.1% YoY. 10-K FY2026 Item 7 'Business and Macroeconomic Environment', 'Net Sales', 'Gross Profit' (inventory/DOI, margins); Q4 FY26 8-K exhibit 2026-05-07 (beat guidance midpoint) |
| Analog attach and proprietary mix would hold ASPs and lead the up-margin mix shift as the franchise recovers. | recurring (10-K MD&A product-line commentary) | In progress | Analog net sales grew 14.9% in FY26 (vs +4.7% MCU), lifting analog to 28.2% of sales from 26.3%; management states analog and MCU ASPs are 'relatively stable' due to proprietary nature. Mix shift up is real but early in the cycle recovery, hence in_progress. 10-K FY2026 Item 7 'Net Sales by Product Line' (Analog +14.9%, 28.2% mix; MCU +4.7%) |
| Maintain the quarterly cash dividend through the downturn ('current intent is to maintain our level of quarterly cash dividends'). | 10-K FY2026 'Dividends and Share Repurchases' | Delivered | Dividend maintained at $0.455/qtr common (declared May 7, 2026), never suspended through the trough. Note: held flat, not raised, and funded partly via $1.45B preferred issuance + higher debt — sustained but at the cost of leverage; buyback effectively paused (no common repurchased in FY26). 10-K FY2026 Item 7 'Dividends and Share Repurchases' ($0.455 dividend; no FY26 buybacks; $1.45B Series A Preferred) |
| June-2026 quarter guidance: net sales midpoint $1.456B (+11% seq), non-GAAP gross margin ~62.25–63.25%, non-GAAP EPS ~$0.67–$0.71. | 2026-05-07 (Q4 FY26 8-K exhibit) | Too early | Forward guidance for the current quarter; not yet reportable. Credible given the prior quarter beat its own midpoint, but unverified as delivered. Q4 FY26 8-K exhibit 2026-05-07 (June-2026 guidance) |
| Pause Fab 4 (Oregon) and Fab 5 (Colorado, incl. SiC/8-inch) capacity expansion through fiscal 2027, resuming as growth requires. | Q4 FY2024 (reaffirmed in 10-K FY2026) | In progress | 10-K FY2026 confirms the pause is still in effect through fiscal 2027 with only select investments continuing — consistent with the stated capital-discipline plan during the downturn; resumption not yet triggered. 10-K FY2026 Item 1 'Wafer Fabrication' (Fab 4/5 expansion paused through fiscal 2027) |
Triangulation chain
A real migration lights up all five: stated → approved → funded → permitted → protected. An announced-only one stalls early.
Strategy is an embedded-control franchise sold as a 'Total System Solution' (TSS) — proprietary 8/16/32-bit and now 64-bit PIC64 RISC-V mixed-signal MCUs/MPUs with attached analog, FPGA, memory, timing and connectivity, targeting AI data center, automotive, aerospace/defense and industrial. Explicit inventory-correction 'business recovery plan' / 'nine-point recovery plan' stated to restore growth and margins. (10-K FY2026 Item 1 Business Overview ('Total System Solution', PIC64 entry July 2024); Item 7 MD&A 'Business and Macroeconomic Environment'; Q4 FY26 8-K exhibit (2026-05-07) CEO Sanghi 'disciplined execution against our nine-point recovery plan')
Board-approved capital actions executed: Dec 2, 2024 Board-sanctioned closure of Fab 2 (Tempe, AZ) to resize manufacturing; March 2025 restructuring (headcount/opex reduction) implemented; Nov-2021 $4.0B buyback authorization; quarterly dividend regime authorized since Oct 2002 and re-declared each quarter. (8-K 2024-12-02 Item 2.05 (Fab 2 closure); 10-K FY2026 Item 7 'Special Charges and Other, Net' and 'Business and Macroeconomic Environment' (March 2025 recovery plan/restructuring); 10-K 'Dividends and Share Repurchases')
Fully self-funded plus capital raises to bridge the trough: FY26 gross profit $2.72B and operating cash flow support the dividend; March 2025 issued 29.7M Depositary Shares (Series A Preferred) for $1.45B net; $5.54B total debt and a $2.25B commercial-paper program provide liquidity. Fab 2 closure targeted ~$90M/yr cash savings; inventory drawn from $1.29B to $1.04B freeing cash. (10-K FY2026 Item 7 'Liquidity and Capital Resources' ($5.54B debt, $1.45B Series A Preferred, CP program); 'Gross Profit' ($2.72B); 8-K 2024-12-02 (~$90M annual cash savings))
Owns and operates US wafer fabs (Fab 4 Gresham OR, Fab 5 Colorado Springs) plus internal assembly/test in Thailand and Philippines; ~35% of FY26 sales from own US fabs. Not a permitting-gated build-out — the current phase is a right-sizing (Fab 2 closed May 2025; Fab 4/5 SiC expansion paused through FY2027), so site/regulatory capacity is in place, not pending. (10-K FY2026 Item 1 'Manufacturing'/'Wafer Fabrication' (Fab 2 closure completed May 2025; Fab 4/5 expansion paused through fiscal 2027; ~35% US-fab sales))
Structural switching costs: proprietary MCU/analog architectures with sticky design-tool ecosystem (customers 'preserve their investment in learning and tools' migrating across the portfolio), ~101,000 unique customers, stable ASPs on proprietary lines. Patent portfolio expiring 2026–2045 plus SuperFlash embedded-flash IP licensed to third-party foundries generating royalties. Defense-grade FPGA/security IP. Management notes it 'vigorously' defends IP vs cloners in China/Taiwan. (10-K FY2026 Item 1 'Patents, Licenses and Trademarks' (patents 2026–2045; SuperFlash licensing), 'Development Tools' (tool lock-in), 'Competition'; Item 7 'Net Sales by Product Line' (proprietary ASP stability))
Catalysts
- U.S. Supreme Court ruled (Feb 20, 2026) certain IEEPA tariffs unconstitutional; CBP began processing refunds Apr 20, 2026 — Microchip was importer of record and expects a potential (unquantified) refund. · 2026-02-20 / 2026-04-20
Potential one-time favorable cash/margin item; size and timing not yet estimable per the filing.
- Section 232 semiconductor investigation leaves finished semis currently exempt from certain U.S. tariffs; Nexperia export-control disruption tightening mature-node supply. · 2025–2026
Mature-node scarcity and reshoring bias favor Microchip's US-fab (~35% of sales) trailing-edge franchise; also a demand risk if customers face component shortages.
- Entry into 64-bit PIC64 RISC-V microprocessors (July 2024) and first 3nm PCIe Gen 6 switch for AI data-center infrastructure. · 2024-07 onward
Extends the proprietary portfolio up-chain into higher-value AI/defense sockets, supporting the mix-shift thesis.
Risk flags
- leverage_governance_watch
Not a value-trap disqualifier but a flagged watch: dividend defended through the trough via $1.45B of 7.50% mandatory-convertible preferred and $5.54B total debt; buyback paused (no FY26 common repurchases); founder-CEO return amid leadership turnover; open transfer-pricing tax disputes. Weighs on G, does not veto the thesis.
Sources
Bridged from SEC EDGAR 10-K + 8-K filings, latest 10-K filed 21 May 2026. Read the 10-K on SEC EDGAR → Provenance: agent-grounded-fulltext. Financials from SEC EDGAR XBRL; price from public market data.